- Home
- ZLAB vs IMCR Comparison
ZLAB vs IMCR Comparison
Compare ZLAB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- IMCR
- Stock Information
- Founded
- ZLAB 2013
- IMCR 2008
- Country
- ZLAB China
- IMCR United Kingdom
- Employees
- ZLAB N/A
- IMCR N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZLAB Health Care
- IMCR Health Care
- Exchange
- ZLAB Nasdaq
- IMCR Nasdaq
- Market Cap
- ZLAB 3.6B
- IMCR 1.7B
- IPO Year
- ZLAB 2017
- IMCR 2021
- Fundamental
- Price
- ZLAB $29.25
- IMCR $33.55
- Analyst Decision
- ZLAB Buy
- IMCR Buy
- Analyst Count
- ZLAB 6
- IMCR 8
- Target Price
- ZLAB $57.22
- IMCR $57.00
- AVG Volume (30 Days)
- ZLAB 555.3K
- IMCR 334.0K
- Earning Date
- ZLAB 11-06-2025
- IMCR 11-05-2025
- Dividend Yield
- ZLAB N/A
- IMCR N/A
- EPS Growth
- ZLAB N/A
- IMCR N/A
- EPS
- ZLAB N/A
- IMCR N/A
- Revenue
- ZLAB $427,799,000.00
- IMCR $356,145,000.00
- Revenue This Year
- ZLAB $41.80
- IMCR $29.71
- Revenue Next Year
- ZLAB $49.93
- IMCR $11.27
- P/E Ratio
- ZLAB N/A
- IMCR N/A
- Revenue Growth
- ZLAB 32.56
- IMCR 26.78
- 52 Week Low
- ZLAB $23.82
- IMCR $23.15
- 52 Week High
- ZLAB $44.34
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- ZLAB 39.82
- IMCR 48.34
- Support Level
- ZLAB $27.81
- IMCR $33.04
- Resistance Level
- ZLAB $30.18
- IMCR $34.90
- Average True Range (ATR)
- ZLAB 1.15
- IMCR 1.31
- MACD
- ZLAB -0.37
- IMCR -0.03
- Stochastic Oscillator
- ZLAB 20.84
- IMCR 38.63
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.